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Introduction
Despite years of suppressive antiretroviral therapy (ART), the vast 
majority of individuals infected with HIV will experience rapid 
viral rebound during an analytic treatment interruption (ATI) (1). 
Efforts to achieve an HIV cure were boosted by the case of the 
Berlin patient who achieved an apparently sterilizing cure with no 
detectable virus after undergoing hematopoietic stem cell trans-
plantation with donor cells that were naturally resistant to HIV 
infection (2). However, this approach has limited generalizability 
given the substantial mortality associated with stem cell trans-
plantation and the rarity of donors with cells resistant to HIV. An 
alternative approach is a functional cure, or sustained HIV remis-
sion, where proviral HIV DNA may still be detectable, but patients 
maintain viral suppression even after ART discontinuation. These 
individuals are termed HIV posttreatment controllers (PTCs). 
The most comprehensive description of PTCs so far has been the 
VISCONTI cohort of 14 PTCs (3). These individuals were treated 
during early HIV infection, but unlike HIV elite controllers (ECs), 
favorable HLA alleles associated with viral control were not over-
represented in these participants. However, PTCs are exceedingly 
rare and the HIV proviral reservoir determinants of posttreatment 
control are largely unexplored. We addressed this question using a 
group of PTCs identified from previously completed AIDS Clinical 
Trials Group (ACTG) studies (4).
HIV DNA and cell-associated RNA (CA-RNA) were detected 
before ATI in PTCs from both the VISCONTI (3) and ACTG (4) 
participants. Currently, a smaller HIV reservoir size is thought 
to be a contributing factor for HIV posttreatment control (5, 6). 
However, PCR-based methods of HIV reservoir quantification of 
proviral DNA overestimate the true reservoir size, as most pro-
viral genomes are defective (7–10). We hypothesized that indi-
viduals with a smaller intact proviral reservoir prior to treatment 
interruption are more likely to be PTCs. To explore this question, 
we performed near-full-length sequencing of proviral genomes 
using next-generation sequencing of single-genome amplicons 
for a group of PTCs and posttreatment noncontrollers (NCs). 
This approach allows for an in-depth assessment of the intact and 
defective HIV reservoir, as well as providing evidence of likely 
clonal expansion. Assessing the types of defective proviruses 
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tiated ART during early HIV infection and 6 who initiated ART 
during chronic HIV infection (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI120549DS1). The median duration of documented viral control 
was 63 weeks for the PTCs. To exclude continued ART use as the 
cause of HIV control, all PTCs underwent drug-level testing and no 
antiretroviral drugs were detectable during the treatment interrup-
tion. These 10 PTCs were compared with 16 NCs from the same 
studies and were well matched in their demographic characteris-
tics (Table 1 and Supplemental Table 1). Nine individuals (4 PTCs 
present (e.g., deleted, hypermutated) provides insight into poten-
tial mechanisms underlying posttreatment HIV control. Further-
more, we assessed the relationship among different proviral spe-
cies, levels of intracellular HIV RNA expression, and host immune 
responses to define the functional capacity of the proviral reser-
voir and immune correlates of reservoir size.
Results
Overview of study population and proviral sequencing. Ten PTCs were 
identified from prior ACTG ATI trials, including 4 PTCs who ini-
Figure 1. Composition of the proviral landscape 
pretreatment interruption. (A and B) For each 
participant, the amplified proviral sequences 
are graphed by amplicon size and type of defect 
and labeled accordingly for PTCs (A) and NCs 
(B). There are 303 proviral genomes shown for 
PTCs and 821 shown for NCs. The number of 
sequences obtained from each participant is 
shown in parenthesis at the top of the graph. 
PSI, packaging signal.
Of note, there was a wide variation in the relative proportion of 
intact proviral genomes, including 8 participants whose viral reser-
voir contained more than 10% intact proviral genomes and 4 indi-
viduals with more than 20% intact proviral genomes.
Interestingly, levels of total proviral genomes (TPGs) were 
7-fold lower in PTCs (median 1.6 vs. 11.1 copies/106 PBMCs, P <
0.001, Figure 3C and Supplemental Figure 2) and were predom-
inantly driven by levels of defective proviral genomes (DPGs, 
median 1.5 vs. 10.8 copies/106 PBMCs, P < 0.001, Figure 3D and 
Supplemental Figure 2). There were no significant differences 
in the percentages of defective proviruses between PTCs and 
NCs (median 98.6% vs. 95.9%, Figure 3E). Among the readouts 
examined (IPGs, TPGs, and DPGs), levels of TPGs were the best 
reservoir marker to differentiate between PTCs and NCs, as 81% 
of NCs versus 0% of PTCs had TPGs greater than 4 copies/106 
PBMCs. No significant correlations between either pre-ATI CD4+ 
count or duration of ART treatment and any of the reservoir size 
measurements were detected. As a sensitivity analysis, we also 
calculated reservoir size per million CD4+ T cells, instead of 
PBMCs, and observed similar findings.
Next, we assessed whether certain types of defective provi-
ruses were overrepresented in PTCs, as they can inform poten-
tial mechanisms underlying HIV control. Within the DPGs, PTCs 
had fewer proviral sequences with large deletions (median 1.1 vs. 
10.5 copies/106 PBMCs, P < 0.001) and fewer hypermutated pro-
viral genomes (HPGs, median 0.2 vs. 1.2 copies/106 PBMCs, P < 
0.01, Figure 3F). However, the percentages of proviral sequences 
with large deletions or hypermutated proviral sequences were 
not significantly different between PTCs and NCs (Figure 3G). 
Furthermore, there was no difference between PTCs and NCs in 
the extent of apolipoprotein B mRNA editing enzyme catalytic 
polypeptide-like (APOBEC)-induced hypermutations relative to 
control (non-APOBEC) mutations (Figure 3H). The median pro-
portions of each proviral species in the PTCs and NCs are shown 
in Figure 3I. In addition, we were interested in exploring whether 
treatment during early versus chronic infection changed the pro-
portion of the different subsets of proviruses. In comparing the 
early and chronic-treated participants, chronic-treated NCs had 
higher levels of TPGs (median 15.7 vs. 2.6 copies/106 PBMCs, P < 
0.05) and DPGs (median 13.3 vs. 2.5 copies/106 PBMCs, P < 0.05) 
compared with early treated NCs, but there were no significant 
differences in percentages of any proviral subset or in the copy 
numbers of IPGs or HPGs (Supplemental Figure 4).
To confirm that the proviral sequences we characterized as 
intact were replication competent, we isolated CD4+ T cells from 
2 study participants, 1A8 (PTC) and 1C114 (NC), for whom large 
numbers of PBMCs were available. The cells were activated and 
cocultured with MOLT-4 cells in a viral outgrowth assay using 
a Transwell system. MOLT-4 cells from wells where virus was 
detected in the supernatant were subjected to near-full-length 
proviral amplification. Sequences obtained for each participant, 
1A8 and 1C114, were nearly identical to the intact provirus, dif-
fering by only 4 and 5 nucleotides out of 9,020 nucleotides, 
respectively. These few nucleotide differences likely represent 
the expected variation arising during the 3-week culture period 
used to obtain each isolate (12, 13) and translated to 1 amino acid 
change in env for 1A8 and 2 changes in env for 1C114. Thus, we 
and 5 NCs) were treated during early infection as part of ACTG 
trial 371 (11), in which participants were treated with at least 52 
weeks of ART prior to undergoing an ATI. The remaining individ-
uals were treated during chronic infection. A median of 7.4 million 
peripheral blood mononuclear cells (PBMCs) were sampled from 
each participant from the pretreatment interruption time point, 
and 1,124 proviral genomes were obtained with a median of 48 
proviral genomes per participant (Q1, Q3: 17, 58). In addition, we 
amplified 326 near-full-length proviral sequences from 7 PTCs at 
a posttreatment interruption time point. All proviral sequences 
were categorized as either intact or defective. The defects included 
internal inversions, hypermutations, deletions, premature stop 
codons, and defects in the packaging signal (psi) (Figure 1). For 
each participant, “genomes per million PBMCs” were calculated 
for total proviral genomes and for each proviral species.
In total, our data set was comprised of 137 intact and 1,313 
defective proviral genomes. Prior to the treatment interrup-
tion, defective proviral genomes constituted the vast majority of 
the HIV reservoir (median 97% of the total proviral genomes), 
although substantial variation among individuals was observed 
(Q1, Q3: 87%, 99%) as demonstrated with 4 representative 
study participants (Figure 2A). To ensure that there was no cross- 
contamination between participant samples, we generated a 
neighbor joining tree including all the intact sequences obtained 
for the study and confirmed that all single-genome sequences 
clustered appropriately (Figure 2B).
Distinct proviral landscapes in PTCs and NCs. Until now, the 
intact proviral reservoir has not been described in PTCs. We 
hypothesized that a smaller intact proviral reservoir size before 
treatment interruption may be a determinant of posttreatment 
control. Our results showed that prior to treatment interruption, 
PTCs had approximately 7-fold lower levels of intact proviral 
genomes than NCs (IPGs, PTCs vs. NCs: median 0.04 vs. 0.28 
copies/106 PBMCs, P < 0.05, Figure 3A and Supplemental Figure 
2). These intact proviral sequences likely represent the replication- 
competent reservoir, as we detected exact matches with plasma- 
derived sequences for a subset of participants (Supplemental Fig-
ure 3). We observed lower percentages of intact proviruses in the 
PTCs compared with NCs, although this difference did not reach 
statistical significance (median 1.4% vs. 4.1%, P = 0.4, Figure 3B). 
Table 1. Demographic characteristics of PTCs and NCs
PTCs (N = 10) NCs (N = 16)
Male, n (%) 8 (80) 11 (68.8)
Age, median, years 42 44
Early treated, n (%) 4 (40) 5 (31.3)
Years on ART, median 4.5 4.5
CD4 count, median 894 802
Race
White, n (%) 7 (70) 10 (62.5)
Black, n (%) 1 (10) 3 (18.8)
Hispanic, n (%) 2 (20) 3 (18.8)
PTCs, posttreatment controllers; NCs, posttreatment noncontrollers; ART, 
antiretroviral therapy.
wanted to confirm that our bioinformatic calls of intact env in these 
proviral sequences reflect true functionality. So we separately tested 
the functionality of env of 4 different intact proviruses, including 1A8 
and 1C114, by cotransfecting env PCR fragments with a Δenv-NL4-3 
plasmid and determined the infectivity of the produced virus in a 
TZM-bl assay. Supplemental Figure 5 shows the infectivity titer for 
4 recombinant viral constructs harboring intact proviral env from 
these participants, indicating that they are functional.
Stability of the intact HIV reservoir after treatment interruption 
in PTCs. Upon treatment interruption, levels of HIV DNA increase 
dramatically in most patients with HIV (14). We wanted to investi-
gate whether this also occurred in PTCs after ATI, especially within 
the intact proviral reservoir. Levels of IPGs, TPGs, and DPGs were 
assayed for 7 PTCs with available samples at a late time point, a 
median of 71 weeks after treatment interruption. Unlike previously 
reported NCs (14), we detected no consistent increases in levels 
of IPGs, TPGs, and DPGs between the pre- and posttreatment 
interruption time points (Figure 3, J–L). The median ratio of pre/ 
posttreatment interruption genomes per million PBMCs was 0.9 
for IPGs, 1.3 for TPGs, and 1.4 for DPGs. No new HIV drug resis-
tance mutations were detected in any of these individuals after 
treatment interruption compared with the preinterruption time 
point (15, 16).
No differences between PTCs and NCs in the clonal expansion 
of cells harboring intact proviral sequences. As illustrated in Figure 
2B, our data set included several participants with a significant 
number of identical intact proviral sequences and likely repre-
sent clonally expanded sequences. Thus, we assessed whether 
the smaller intact proviral reservoir detected in PTCs is caused 
by differential rates of clonal expansion. To investigate this, we 
assessed the percentage of identical proviral sequences detected 
more than once and found no significant differences between 
PTCs and NCs in the proportion of clonally expanded provi-
ral genomes. This was true regardless of whether the clonally 
expanded populations harbored intact (PTCs vs. NCs: median 
0% in both cases) or defective proviral sequences (median 14% 
vs. 17%, Figure 4A and Supplemental Figure 6). Likewise, the 
absolute number of IPGs detected more than once was not sig-
nificantly different between PTCs versus NCs, although PTCs 
did have a smaller number of DPGs detected more than once 
(median 0.2 vs. 2.7 copies/106 PBMCs, P < 0.01, Figure 4B). A 
sensitivity analysis of only participants who initiated ART during 
chronic infection yielded similar results. Of note, there were 4 
participants who harbored a high percentage of clonal intact 
proviruses, 3 of whom initiated ART during chronic infection 
Figure 2. Near-full-length, single-template HIV-1 DNA amplicons. (A) 
Virograms reflecting the diversity of HIV DNA PCR products amplified 
from 4 representative participants (2 PTCs and 2 NCs, all treated during 
chronic infection). Numbers in parentheses indicate absolute frequency 
of analyzed sequences in each participant. (B) Combined neighbor-joining 
phylogenetic tree for all 137 intact proviral sequences showing no evidence 
of cross-participant sequence contamination, with HXB2 as an outgroup. 
Participants with more than 1 intact near-full-length proviral sequence are 
colored and those with only 1 identified intact sequence are depicted in 
black. The IDs of each participant are shown to the right of the tree. Aster-
isks denote clonal sequences detected more than once. PTC, posttreat-
ment controllers; NC, posttreatment noncontrollers; PSI, packaging signal.
by near-full-length sequencing was on average 75% (Q1, Q3: 
61%, 82%) of the frequency determined by integration site anal-
ysis. Supplemental Table 2 contains a list of all integration sites 
obtained from these participants.
A possible driver of clonally expanded cells harboring intact 
proviruses could be T cell activation, given that it precipitates cel-
lular proliferation and clonal expansion. However, we observed 
no significant correlation between percentages of HLA-DR+ 
CD38+ CD4+ or CD8+ T cells and either the proportion or absolute 
numbers of clonally expanded IPGs and DPGs.
(31% for patient 1C16, 26% for patient 1C104, and 9% for patient 
1C116, Figure 4C) and 1 treated during early infection (21% for 
patient 1A5). These intact sequences could be grouped into a few 
clusters of identical sequences with the largest 2 clusters com-
prising at least 50% of all expanded intact sequences. Integration 
site analysis for these 4 participants support the near-full-length 
proviral sequencing results, showing that clonality estimates 
calculated by identical near-full-length proviral genomes were 
similar to those calculated from integration site analysis (Figure 
4D). The frequency of clonally expanded sequences determined 
Figure 3. Comparison of reservoir measures between PTCs and NCs. (A) Copy numbers and (B) percentages of intact proviral genomes within total reser-
voir are compared between both groups. (C) Copy numbers of total proviral genomes per million PBMCs are compared between groups. (D) Copy numbers 
and (E) percentages of defective proviral genomes are depicted for each group. (F) Copy numbers and (G) percentages of hypermutated proviral genomes 
are depicted for each group. The size of each data point corresponds to total number of sequences amplified per participant as indicated in the legend in 
A–G. (H) A comparison between PTCs and NCs in the hypermutation rate ratio, calculated as the ratio of the number of match sites out of potential sites 
to the number of control sites out of potential sites. (I) Pie charts reflecting the median relative contribution of each proviral species for all participants, 
normalized to 100%. Numbers in parentheses indicate absolute frequency of analyzed sequences in each group. (J–L) Longitudinal analysis of intact (J), 
total (K), and defective (L) proviral genome copy numbers from the pre- and post-ATI time points for 7 PTCs. Each PTC is shown in a different color. Signif-
icance was calculated using a Wilcoxon rank-sum test: *P < 0.05, **P < 0.01, ***P < 0.001. NCs are depicted in blue and PTCs in red. PTC, posttreatment 
controllers; NC, posttreatment noncontrollers; PSI, packaging signal; PSC, premature stop codon.
HLA typing and HLA-associated escape polymorphisms. In 
order to examine the role of protective HLA alleles in posttreat-
ment control, we analyzed available HLA typing for 6 of the 
PTCs and 11 of the NCs treated during chronic infection. Over-
all, protective HLA alleles were rare and found in only 1 partic-
ipant of each group. We next surveyed for evidence of immune 
pressure on the proviral reservoir by examining inferred HLA- 
associated escape mutations within gag, pol, and nef in the con-
text of each participant’s HLA class I profile (17). Inferred escape 
mutations matching the participants’ HLA allele(s) were present 
at a median of 25% of possible amino acid sites in gag, 17.4% in 
pol, and 25.8% in nef across all participants (Supplemental Figure 
7, A–C). There were no significant differences between PTCs and 
NCs in the extent of mutations detected (Supplemental Figure 7, 
D–F). We also analyzed the proportion of inferred HLA escape 
mutations after treatment interruption in 4 PTCs and observed 
a modest increase in the percentage of HLA escape sites for at 
least 1 gene in 3 of the 4 individuals (Supplemental Figure 7, 
G–I). Trends in the longitudinal changes of the percentage of 
HLA escape sites for the intact proviruses were 
generally mirrored for the defective proviruses.
Defective proviral genome copies are associated 
with levels of CA-RNA and timing to viral rebound. 
Levels of intracellular HIV RNA expression have 
been shown to predict the timing of viral rebound 
after treatment interruption (1, 18). Thus, we 
assessed whether levels of intact provirus cor-
related with both levels of CA-RNA, as well as 
timing to viral rebound. Contrary to our expec-
tations, the number of preinterruption IPGs 
was not significantly associated with unspliced 
CA-RNA levels as quantified by qPCR. However, 
the number of TPGs and DPGs were associated 
with levels of CA-RNA (r = 0.50, P < 0.05, Figure 
5A and Supplemental Figure 8A). In addition, the 
number of TPGs and DPGs, but not IPGs, predict-
ed the timing of subsequent viral rebound after 
ATI (Figure 5B and Supplemental Figure 8B). 
Individuals with late viral rebound (≥ 400 HIV-
1 RNA copies/ml) were found to have the lowest 
TPG and DPG numbers (viral rebound >16 weeks 
vs. 4–16 weeks vs. <4 weeks = median DPGs 1.5 
vs. 9.1 vs. 13.0 copies/106 PBMCs, respectively). 
There was no association among the levels of any 
specific type of defective sequences and either 
levels of CA-RNA or timing to viral rebound.
Association of defective proviral genomes with 
both innate and adaptive immune responses. 
Next, we hypothesized that the intact proviral 
reservoir size is dictated by levels of immune 
activation and the strength of the HIV-specific 
cellular immune response. Immune phenotyp-
ing was performed for CD4+/CD8+ T cells and 
NK cells for markers of activation and cellular 
exhaustion prior to treatment interruption. The 
extent of NK cell function and HIV gag-specific 
T cell responses were assessed by intracellular 
cytokine staining. Amongst all participants, none of the NK cell 
phenotypes or T cell responses were associated with levels of 
IPGs. However, higher CD38+ NK cell percentages were asso-
ciated with lower numbers of DPGs (r = –0.46, P < 0.05, Figure 
5C). Similarly, higher levels of HIV-specific CD8+ cells express-
ing CD107a and HIV-specific IFN-γ–secreting CD4+ cells were 
both associated with lower DPGs (CD8+ CD107a+: r = –0.51, 
P < 0.05; CD4+ IFN-γ+: r = –0.48, P = 0.06; Figure 5, D and E). 
Given that the vast majority of the proviruses are defective, all 
the trends described are also true for TPGs (Supplemental Fig-
ure 8, C–E). There was no association among the levels of spe-
cific types of defect and any of the innate or adaptive immune 
responses. Furthermore, there were no significant associations 
between TPGs, DPGs, or IPGs and levels of soluble inflammatory 
markers D-dimer, IL-6, IP10, sCD14, sCD163, or CRP (Supple-
mental Figure 9).
Common motifs present at proviral deletion junctions. Given the 
high frequency of proviruses with large deletions, we assessed the 
presence of common motifs at the site of proviral deletions and 
Figure 4. Contribution of clonal sequences to the proviral reservoir. (A) No difference between 
PTCs and NCs in percentages of either intact or defective proviral genome copies detected more 
than once. (B) PTCs have lower numbers of defective proviruses detected more than once, but no 
difference in intact copy numbers. Significance was calculated using a Wilcoxon rank-sum test, 
**P < 0.01. (C) Analysis of 4 participants who harbored a high percentage of intact proviruses 
detected more than once. Different stripe patterns depict different clones. Total number of 
amplicons is shown above each bar. (D) Integration site analysis of the same 4 participants in 
C. Different stripe patterns depict different clones. Total number of integration sites is shown 
above each bar. PTC, posttreatment controllers; NC, posttreatment noncontrollers.
found that repeat elements were detected at the deletion junction 
in 11% of the proviral genomes with large deletions (Figure 6A). 
These repeat elements ranged in size from 3 to 20 nucleotides 
(Figure 6B). Interestingly, one specific repeat element residing 
at HXB2 coordinates 4781–4800 (TTTTAAAAGAAAAGGG-
GGGA) flanked the deletion junctions in 16 different proviral 
sequences originating from 8 study participants (2 PTCs and 
6 NCs, Figure 6C). This element maps to both the polypurine 
tract located in pol (cPPT), as well as in nef/U3 (3′PPT) and likely 
represents a hotspot for deletion. This sequence functions as a 
primer site for plus strand DNA synthesis and has been previously 
studied for its role in HIV replication (19–21).
Discussion
Up until now, the best-studied PTCs are the VISCONTI cohort (3, 
22), but other isolated cases of PTCs have also been described (18, 
23–32). In the VISCONTI study, 14 acutely treated participants 
were found to have levels of HIV DNA that were substantially 
lower than that of ART-treated individuals previously described 
in the literature (3). However, it is clear that the vast majority of 
the HIV DNA reservoir is comprised of replication defective provi-
ruses (7–10, 33) and an in-depth analysis of the proviral reservoir, 
including the frequency of intact proviruses, has yet to be per-
formed for any of these PTCs. In this study, we provide the first 
detailed survey of the proviral genomic landscape in a PTC cohort 
and contrast it with that of NCs.
Our results show that prior to treatment interruption, the DNA 
reservoir size, defined as either total or intact proviral genomes, 
was a median 7-fold lower in PTCs than in NCs. Specifically, 81% of 
NCs had greater than 4 total proviral genome copies/106 PBMCs, 
whereas none of the PTCs had a total reservoir size that reached 
this threshold. Low levels of total HIV DNA have been previously 
associated with short-term delays in viral rebound timing (29, 34), 
as exemplified by the report of 2 Boston patients who underwent 
allogeneic hematopoietic stem cell transplantation with suscep-
tible donor cells. In both patients, proviral DNA was reduced to 
undetectable levels after transplantation and viral rebound was 
delayed until 12 and 32 weeks after ATI despite an immune system 
that was functionally naive to HIV (35). This observation led some 
to predict that at least a 3- to 4-log10 reduction in the HIV reservoir 
Figure 5. Relationship between defective pro-
viral genome copy numbers and viral as well as 
immune markers. (A) Correlation between levels 
of cell-associated HIV RNA and copy numbers of 
defective proviral genomes. (B) Individuals with 
delayed viral rebound had lower levels of defective 
proviral genomes. Significance was calculated 
using a Wilcoxon rank-sum test: *P < 0.05, ***P < 
0.001. (C) Correlation between percentage of CD38+ 
NK cells and copy numbers of defective proviral 
genomes. (D) Correlation between percentage of 
HIV-specific CD107+ CD8 T cells and copy numbers of 
defective proviral genomes. (E) Correlation between 
percentage of HIV-specific IFN-γ+ CD4 T cells and 
copy numbers of defective proviral genomes. NCs 
are depicted in blue and PTCs in red. Correlations 
between reservoir measures were estimated with 
nonparametric Spearman correlation coefficients. 
PTC, posttreatment controllers; NC, noncontrollers.
could contribute to the prediction of sustained HIV remission. PTCs 
had a greater variation in the number of intact proviral genomes 
that hindered its use in differentiating between the 2 groups. In 
particular, more than 40% of the total proviral reservoir for PTC 
patient 1C16 was intact, including 2 large clonal populations. This 
observation highlights that the role of the intact proviral reservoir 
size in predicting the timing of viral rebound remains unclear, which 
may be due to its low frequency within the proviral landscape. Addi-
tional analysis of transcriptional activity, integration sites, and viral 
replication fitness of these intact proviruses is needed.
Similar to previously published reports (7–10, 33), we found 
that the vast majority of proviral genomes amplified from 
participant-derived DNA were defective and only a small pro-
portion had intact open reading frames. This was true both for 
participants treated in either the early or the chronic stage of 
HIV infection. We were intrigued to find that for PTCs, the pro-
portion of intact proviruses was almost 3 times lower (1.4%) than 
in NCs (4.1%), although this comparison did not reach statistical 
significance and the characterization of additional participants 
is needed to further explore this finding. We also found no sig-
may be needed to achieve sustained HIV remission (36, 37). Our 
finding of a substantial difference in time to rebound between 
PTCs and NCs despite relatively modest (7-fold) differences in 
total and intact proviral genomes suggests that factors in addition 
to reservoir size must play an important role in determining time 
to rebound. Such factors could include differences in viral replica-
tion rate and/or robust anti-HIV immune responses. This is under-
scored by the finding that despite prolonged treatment interrup-
tion, levels of total and intact proviral reservoir did not significantly 
increase in PTCs, similar to results from the VISCONTI study. This 
finding contrasts with the pattern reported for other HIV-infected 
subjects, where the HIV DNA burden markedly increases upon 
treatment interruption due to viral replication (14, 38, 39).
Given the rarity of PTCs and safety concerns involving treat-
ment interruption studies, future HIV cure trials would benefit 
from a set of biomarkers that could predict which participants are 
more likely to be PTCs prior to treatment interruption. Our finding 
that the majority of NCs, but none of the PTCs, had greater than 
4 total proviral genomes/106 PBMCs before treatment interruption 
suggests that quantification of total proviral genome copy numbers 
Figure 6. Detection of repeat elements at HIV proviral deletion junctions. (A) Illustration of a common pattern present flanking both ends of the dele-
tion junction. (B) Histogram of number of proviral genomes detected with repeat elements of varying lengths. One specific 20 base nucleotide repeat is 
overrepresented. (C) Histogram of the number of times each repeat was detected. nts, nucleotides.
overall true reservoir size within the body, including within ana-
tomic sites, and (b) given the low frequency of intact proviruses, it 
is difficult to detect a relationship with timing of viral rebound and 
a larger sample may be needed.
The limitations of this study should also be acknowledged. 
First, there were individuals with extremely small reservoir sizes 
and relatively few amplified proviral sequences. This may affect 
the accuracy of the estimated frequency of different proviral 
species. However, the results were largely unchanged if the anal-
ysis was restricted to only participants with more than 20 pro-
viral sequences. Second, in vitro reconstitution of the reported 
full-length intact proviruses is needed to confirm that they are 
indeed replication competent (9), although we were able to detect 
identical matches between intact proviral and plasma-derived 
sequences and obtained highly similar sequences in viral out-
growth assays.
In this report, we provide the most comprehensive survey 
to date of the proviral landscape in both PTCs and NCs prior to 
treatment interruption. The results highlight the restricted intact 
and defective HIV reservoir in PTCs and suggest that total provi-
ral genome burden could act as the first biomarker for identifying 
PTCs. Additional studies are needed to confirm these findings 
and to explore whether inefficient viral replication and/or robust 
anti-HIV immune responses are also present in these individu-
als. We also found that the size of the defective proviral reservoir 
was associated with levels of CA-RNA and several NK and T cell 
markers. Until recently, the defective proviral reservoir appears 
to have been underappreciated, but these results support the con-
cept that defective proviruses are far from quiescent (46) and are 
likely playing key roles in immune activation, shaping anti-HIV 
immune responses, and may be a marker of the timing of plasma 
viral emergence after ART discontinuation.
Methods
Study population and samples. PTCs were identified from several ACTG 
analytic treatment interruption studies (11, 47–50). PTCs were defined 
as individuals who were on suppressive ART and after ATI, maintained 
viral loads of no more than 400 HIV RNA copies/ml for at least 24 weeks 
(short-term [≤ 2] viral loads > 400 HIV RNA copies/ml were not exclu-
sionary). Post-ATI plasma samples were tested for ART levels and drugs 
were not detected. NCs were individuals with available stored samples 
who did not meet the PTC criteria and selected to match the same study 
arms. All participants had PBMC samples available immediately before 
ATI (i.e., baseline) for near-full-length proviral sequencing. For a sub-
set of participants with available samples, proviral sequencing was also 
performed on a post-ATI time point collected a median of 71 weeks (Q1, 
Q3: 45 weeks, 84 weeks) after ART discontinuation.
Specifically, early treated participants were stratified by prede-
termined criteria in the original study protocol to either the acute 
infection group or the recent infection group (11). Acute infection was 
defined as having a plasma HIV RNA concentration more than 2,000 
copies/ml within 14 days of study entry and either a negative ELISA, 
or a positive ELISA but a negative or indeterminate Western blot, or a 
positive ELISA and Western blot in conjunction with either a negative 
ELISA or a plasma HIV RNA concentration less than 2,000 copies/
ml in the 30 days prior to entry. The general intention of these criteria 
was to identify cases in which HIV infection had occurred within the 4 
nificant differences in the frequency of any particular defective 
proviral species between PTCs and NCs. Of note, our analysis of 
defective proviral genomes revealed the proportionally higher 
prevalence of a specific proviral deletion, represented in 8 dis-
tinct participants and reported previously in 2 other cohorts 
(8, 9). This pattern comprises a 20 nucleotide repeat sequence 
flanking the deletion junction, representative of the polypurine 
tract, and appears to be a hotspot for proviral deletions.
HIV integration site analysis has suggested that clonal pro-
liferation of HIV-infected cells may play an important role in the 
proliferation and persistence of HIV-infected cells (40, 41). Other 
groups have shown that clonally expanded populations of HIV- 
infected cells can harbor intact, replication-competent proviruses 
(12, 33, 42, 43). A recent report provided definitive evidence that 
latent cells that can be reactivated can arise by clonal expansion in 
vivo by determining that the cells harbored identical TCR sequences 
through scRNA-seq (44). Thus, we evaluated whether clonal 
expansion of intact proviruses could be playing a role in the res-
ervoir size differences between NCs and PTCs by assessing the 
number and frequency of identical proviral sequences detected 
more than once. We observed no difference between PTCs and NCs 
in the proportion of identical intact proviral sequences detected 
more than once. This suggests that the clonal expansion rate of cells 
harboring intact proviruses is similar between PTCs and NCs and 
therefore does not explain the smaller reservoir size in PTCs or their 
ability to maintain viral suppression.
We also evaluated the relationship between the proviral land-
scape and both levels of viral transcription and immune activity. The 
level of unspliced CA-RNA during suppressive ART has been shown 
in several studies to be predictive of the timing of viral rebound 
after ART discontinuation (1, 18), which suggested that CA-RNA 
may largely reflect transcription of the intact provirus. Surprisingly, 
we found that the level of total and defective but not intact proviral 
genomes was significantly associated with CA-RNA levels (Figure 
5A and Supplemental Figure 8A). These results reinforce a recent 
finding that defective proviruses express intracellular HIV RNA 
(45) and that the bulk of the CA-RNA quantified is likely defective 
given that the vast majority of proviruses are replication incompe-
tent (8, 9, 46). Any relationship between the size of the intact proviral 
reservoir and CA-RNA levels is likely obscured by the overwhelm-
ing number of defective proviruses also expressing HIV RNA.
In addition, we found an association between higher levels of 
NK cell activation and HIV-specific T cell activity with lower levels 
of total and defective proviral genomes. This suggests that a more 
robust HIV-specific immune response can identify and effectively 
eliminate HIV-infected cells, even those harboring defective pro-
viruses. Combined with the CA-RNA results, these findings sup-
port the concept that defective HIV genomes can lead to viral RNA 
transcription and antigen production (8, 46), which leads to inter-
actions of cells harboring defective HIV genomes with both the 
innate and adaptive immune system. Further studies are needed 
to explore this finding.
We also found that the level of defective but not intact provi-
ral genomes was associated with the timing of viral rebound after 
ART interruption. The reason behind this counterintuitive result 
is unclear, but possible explanations include: (a) the size of the 
defective proviral genome within the peripheral blood reflects the 
(Qiagen). Unspliced CA-RNA levels were quantified using a real-time 
PCR approach with primers/probes targeting conserved regions of 
HIV LTR/gag as previously described (1). Cell numbers were quanti-
fied by qPCR measurements of CCR5 DNA copy numbers. Measure-
ment of IPO-8 transcripts in total RNA was used as an internal quality 
control to assess the efficiency of RNA extraction (56).
Immune phenotyping and intracellular cytokine staining. Approx-
imately 106 PBMCs each were used for T and NK cell phenotyping. 
T cells were stained with blue viability dye (Invitrogen) at 37°C 
for 20 minutes and then followed with antibodies targeting CD3, 
CD8, CD4, CD45RO, CD95, HLA-DR, CD38, and PD-1 at 4°C for 
20 minutes. NK cells were stained with blue viability dye and anti-
bodies targeting CD3, CD19, CD16, CD56, CD69, CD38, CD57, 
NKG2D, NKp30, and NKp46.
T cell intracellular cytokine staining (ICS) was performed on 
PBMCs stimulated with HIV gag peptide pool and NK cell ICS was per-
formed with PBMCs stimulated with K562 cells. For T cells, approx-
imately 106 cells were stimulated overnight with anti-CD28/49d 
(0.5 μg/ml; BD Biosciences) and 2 μg/ml of synthetic peptides (over-
lapping 15- to 20-mer gag peptide pools spanning the entire clade B 
consensus sequence of the HIV-1 gag sequence). NK cells were stimu-
lated with K562 cells with an effector-to-target ratio of 10:1. Brefeldin 
A (1 μg/ml; BioLegend), Monesin Solution (1 μg/ml; BioLegend), and 
CD107a antibody were added after a 1-hour incubation and cultured 
for an additional 5 hours. Cells stimulated with PMA (2.5 μg/ml) and 
ionomycin (0.5 μg/ml) served as a positive control and R10 medium 
alone served as a negative control. After stimulation, the cells were 
stained with surface antibodies against CD3, CD19, CD16, CD56, 
and blue viability dye at 4°C for 20 minutes. Subsequently, cells 
were treated with a fixation and permeabilization solution per the 
manufacturer’s protocol. Cells were stained for 20 minutes at room 
temperature with antibodies directed to IFN-γ, IL-2, CD107a, and 
TNF-α. Cells were then fixed by 2% PFA (Affymetrix), acquired on an 
LSR Fortessa flow cytometer (BD Biosciences), and analyzed using 
FlowJo software (version v10, Tree Star). The proportion of cytokine- 
secreting cells had to be greater than 0.1% after subtraction to be 
considered as a positive response.
Soluble markers of inflammation. Soluble markers of inflammation 
were measured by ELISA. Plasma from all participants was analyzed 
for levels of IL-6 (HS600B, R&D Systems), sCD14 (DC140, R&D 
Systems), IFN-γ, IP10 (DIP100, R&D Systems), sTNFR-I and sTN-
FR-II (DRT100/200, R&D Systems), and D-dimer (Diagnostica 
Stago) per the manufacturers’ protocols.
Infectivity of recombinant viruses. We generated recombinant viri-
ons encoding patient-derived env sequences by cotransfecting 293T 
cells with Δenv-NL4-3 plasmid and env PCR fragments. Virus was 
harvested and propagated in U87-CCR5 and U87-CXCR4 cells for 
7–10 days. Afterwards, we tested the infectivity of the virus in a TZM-
bl infectivity assay. TZM-bl cells (NIH AIDS Reagent Program) are a 
permissive HeLa cell clone that contains a Tat-regulated reporter gene 
for β-galactosidase under the control of the HIV-1 LTR.
Integration site analysis. Integration sites were determined using 
the integration site loop amplification (ISLA) technique on genomic 
DNA isolated from PBMCs before treatment interruption, as previ-
ously published (41).
Viral outgrowth assays. CD4+ T cells were isolated by negative 
selection and stimulated with PHA (2 μg/ml), rhIL-2 (50 U/ml), and 
weeks prior to study entry. Recent infection was defined as a positive 
ELISA and Western blot within the 14 days prior to entry but a negative 
ELISA or plasma HIV RNA concentration less than 2,000 copies/ml 
within the 31 to 90 days before entry or a positive ELISA and Western 
blot and a nonreactive detuned ELISA in patients with more than 200 
CD4+ cells/μl all within the 21 days before study entry.
Proviral sequencing. Next-generation single-genome sequenc-
ing (NG-SGS) utilizes the Illumina deep sequencing platform to 
efficiently sequence the single-genome, near-full-length proviral  
amplicons. Single-genome sequencing allows the isolation of full-
length proviral HIV without the confounding concerns of PCR 
recombination frequently seen in bulk PCR products. Limiting dilu-
tion proviral amplification was performed using a technique adapted 
from a previously published protocol (51). DNA was extracted from 
cryopreserved PBMCs using the QIAmp DNA Mini Kit (Qiagen) and 
used at limiting dilution for nested PCR amplification with Platinum 
Taq HiFi polymerase (Thermo Fisher Scientific). The sequences 
of the primers for the first- and second-round PCR reactions were 
as follows: first-round forward primer: 5′-AAATCTCTAGCAGT-
GGCGCCCGAACAG-3′, first-round reverse primer: 5′-TGAGG-
GATCTCTAGTTACCAGAGTC-3′; second-round forward primer: 
5′-GCGCCCGAACAGGGACYTGAAARCGAAAG-3′, second-round 
reverse primer: 5′-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3′. 
These primers correspond to HXB2 coordinates 623–649, 9662– 
9686, 638–666, and 9604–9632, respectively. PCR amplicons  
were sheared and Illumina barcoded libraries were constructed 
and pooled. Sequencing was performed on the Illumina MiSeq plat-
form and amplicons were assembled using the UltraCycler v1.0. 
Automated de novo sequence assembly generated a continuous 
fragment of HIV-1 proviral DNA, which was fed into an automated  
in-house pipeline to determine proviral genome intactness (52), 
as previously published (33). Briefly, the sequences were aligned 
to HXB2 to identify sequence defects (e.g., internal deletions, pre-
mature stop codons, out-of-frame mutations, internal inversions, 
and packaging signal defects). The sequences were then run in the 
Los Alamos HIV Sequence Database Hypermut program to identify  
hypermutated sequences (53). Proviral sequences that lacked any 
of the above-mentioned defects were classified as intact. Near- 
full-length assembled sequences missing one of the PCR primer 
binding sites, but otherwise meeting the criteria for an intact pro-
virus, were labeled “inferred intact.” A clonal cluster analysis was 
also performed to detect genomes that were 100% identical across 
the entirety of their assembled length. The unit “genomes per mil-
lion PBMCs” was calculated for total proviral genomes and for each  
proviral species based on the quantity of DNA assayed.
Additionally, proviral sequences were analyzed in the context 
of each participant’s HLA class I profile for the presence of known 
HLA-associated polymorphisms in HIV-1 subtype B as defined in a 
published reference list (17). We also assessed the presence of repeat 
elements flanking the deletion junctions using a Python script.
Plasma viral sequencing. Plasma viral RNA was extracted using the 
QIAamp Viral RNA Mini Kits and SGS of HIV-1 pro-rt (HXB2 coordi-
nates 2853–3869) performed as previously published (54, 55). Using 
ClustalW, the resulting plasma-derived single-genome sequences 
were aligned with proviral sequences harboring the pro-rt region.
Quantification of HIV DNA and CA-RNA. CA-RNA was isolated 
from cryopreserved PBMCs using the AllPrep DNA/RNA Mini Kit 
DMM, RM, PV, and EC contributed samples. All authors were 
involved in the writing of the manuscript.
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